MAIA Biotechnology, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity - Additional Information (Details)

Stockholders' Equity - Additional Information (Details) - USD ($)												3 Months Ended
	Mar. 28, 2024	Mar. 14, 2024	Feb. 14, 2024	Nov. 17, 2023	Nov. 15, 2023	Nov. 13, 2023	Nov. 09, 2023	Sep. 28, 2023	May 25, 2023	Aug. 03, 2022	Aug. 01, 2022	Mar. 31, 2024	Mar. 31, 2023	Mar. 25, 2024	Dec. 31, 2023	Dec. 31, 2021
Subsidiary or Equity Method Investee [Line Items]
Common stock, shares authorized											70,000,000	70,000,000			70,000,000
Preferred stock, shares authorized											30,000,000	30,000,000			30,000,000
Common stock, par value												$ 0.0001			$ 0.0001
Warrants exercise price, per share	$ 2.55	$ 1.3									$ 6.25
Stock options outstanding												8,060,978			7,750,152
Fair value assumptions, contractual term												7 years
Exercise price percentage												110.00%
Percentage of shares granted												10.00%
Warrants to purchase aggregate of common stock												452,731
Warrants and rights exercisable period											Jan. 23, 2023
Class of warrant or right date from which warrants or rights expire											Jul. 27, 2027
Loss (gain) on remeasurement of warrant liability												$ 4,181,298	$ (20,942)
Share Repurchase Program
Subsidiary or Equity Method Investee [Line Items]
Common stock, par value								$ 0.0001
Share repurchase program expiration period								2024-09
Shares repurchased												0
Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Risk free interest rate										2.82%		4.20%
Volatility rate										77.50%		95.00%
Fair value assumptions, contractual term										5 years		5 years 6 months
Warrants										$ 343,735		$ 230,685
Maximum
Subsidiary or Equity Method Investee [Line Items]
Fair value assumptions, contractual term												10 years
Warrants to purchase aggregate of common stock											100,000
Maximum \| Share Repurchase Program
Subsidiary or Equity Method Investee [Line Items]
Share repurchase authorized amount								$ 800,000
2018 Stock Option Plan
Subsidiary or Equity Method Investee [Line Items]
Common stock reserved for issuance												0
Stock options outstanding												1,924,500
Amended and Restated 2020 Equity Incentive Plan
Subsidiary or Equity Method Investee [Line Items]
Common stock reserved for issuance												0
Stock options outstanding												3,532,125
2021 Equity Incentive Plan
Subsidiary or Equity Method Investee [Line Items]
Common stock reserved for issuance											1,909,518	4,098,243			2,838,668	1,956,993
Stock options outstanding												2,604,353
Percentage of increase in stock outstanding fully diluted									10.00%
IPO \| Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Warrants												$ 112,878			$ 40,211
Loss (gain) on remeasurement of warrant liability												72,666
Overallotment Option \| Maximum
Subsidiary or Equity Method Investee [Line Items]
Class of warrant or right additional purchase aggregate of common stock										15,000
At The Market Offering Agreement \| H.C. Wainwright and Co., LLC
Subsidiary or Equity Method Investee [Line Items]
Common stock, par value			$ 0.0001
Number of common stock Issued and sold			507,754
Common stock per share			$ 1.47
Gross proceeds from sale of common stock			$ 745,251
Percentage of gross proceeds of offerings			3.00%
Private Placement
Subsidiary or Equity Method Investee [Line Items]
Common stock per share	$ 2.295	$ 1.17
Aggregate purchase price	$ 1,330,000	$ 2,920,000
Warrants exercise price, per share		$ 1.3
Warrants and rights exercisable period		Sep. 14, 2024
Class of warrant or right date from which warrants or rights expire		Sep. 14, 2029
Warrants												3,793,921
Loss (gain) on remeasurement of warrant liability												1,744,321
Private Placement \| Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Risk free interest rate		4.20%
Volatility rate		95.00%
Fair value assumptions, contractual term		5 years 6 months
Warrants		$ 2,049,600
Private Placement Offering
Subsidiary or Equity Method Investee [Line Items]
Warrants and rights exercisable period	Sep. 28, 2024
Class of warrant or right date from which warrants or rights expire	Sep. 28, 2029
Warrants												973,980
Loss (gain) on remeasurement of warrant liability												216,131
Private Placement Offering \| Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Risk free interest rate	4.20%
Volatility rate	95.00%
Fair value assumptions, contractual term	5 years 6 months
Warrants	$ 1,190,111
Registered Direct Offering
Subsidiary or Equity Method Investee [Line Items]
Warrants exercise price, per share				$ 1.86	$ 2.06
Risk free interest rate				3.85%	3.84%
Volatility rate				90.00%	90.00%
Fair value assumptions, contractual term				5 years 4 months 17 days	4 years 10 months 17 days
Warrants to purchase aggregate of common stock					169,697
Warrants and rights exercisable period					Nov. 15, 2023
Class of warrant or right date from which warrants or rights expire					Nov. 15, 2028
Warrants				$ 1,903,915	$ 123,811							280,770			123,811
Loss (gain) on remeasurement of warrant liability												156,959
Registered Direct Offering \| Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Warrants												4,211,746			1,903,915
Loss (gain) on remeasurement of warrant liability												$ 2,307,832
Registered Direct Offering \| Maximum
Subsidiary or Equity Method Investee [Line Items]
Warrants to purchase aggregate of common stock				2,424,243
Common Stock \| At-the-Market Equity Offering
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold												507,754
Common Stock \| At The Market Offering Agreement \| Maximum \| H.C. Wainwright and Co., LLC
Subsidiary or Equity Method Investee [Line Items]
Aggregate offering price			$ 1,445,000											$ 4,950,000
Common Stock \| Private Placement
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold	578,643	2,496,318
Investor Warrants \| Private Placement
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold	578,643	2,496,318
Common stock per share	$ 2.55	$ 1.3
Investor Warrants \| Private Placement Offering
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold	578,643
Common stock per share			$ 2.55
Oustside Investors Warrants \| Private Placement Offering
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold		2,043,587
Restricted Stock Awards
Subsidiary or Equity Method Investee [Line Items]
Stock compensation expense												$ 11,500	$ 164,070
Shares granted												12,500	40,500
Unvested shares												0
Employee Stock Option \| Maximum
Subsidiary or Equity Method Investee [Line Items]
Fair value assumptions, contractual term												6 years 29 days	6 years 29 days
Employee Stock Option \| Minimum
Subsidiary or Equity Method Investee [Line Items]
Fair value assumptions, contractual term												5 years	5 years
Alumni Capital LP
Subsidiary or Equity Method Investee [Line Items]
Warrants exercise price, per share							$ 2.09
Risk free interest rate							3.93%
Volatility rate							90.00%
Warrant fee paid in cash							$ 13,750
Fair value assumptions, contractual term							3 years 10 months 13 days
Warrants and rights exercisable period							Nov. 10, 2023
Class of warrant or right date from which warrants or rights expire							Nov. 10, 2027
Warrants							$ 84,251					$ 199,902			$ 84,251
Warrant shares vested						131,578
Loss (gain) on remeasurement of warrant liability												$ 115,651
Alumni Capital LP \| Maximum
Subsidiary or Equity Method Investee [Line Items]
Warrants to purchase aggregate of common stock							239,234